SAN FRANCISCO, Aug. 6, 2026 /PRNewswire/ -- Hagens Berman encourages investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) who suffered substantial losses to submit your losses now . A securities fraud class action lawsuit has been filed against Capricor, and investors are encouraged to contact the firm regarding potential recoveries and lead plaintiff rights.